ESH Video

2nd International Conference on New Concepts in B-Cell Malignancies

Chairs: Michael Hallek, Louis Staudt, Stephan Stilgenbauer, Andrei Thomas-Tikhonenko

SESSION I: MOLECULAR MECHANISMS OF B-CELL NEOPLASMS – FROM GENOME TO DIAGNOSTIC TOOLS AND PROGNOSTIC PREDICTION

Bcl-6 and related pathways in lymphomagenesis – Riccardo Dalla-Favera

B-cell receptor mediated signaling and the use of targeted therapies – Louis Staudt

Pre-B-Cell receptor signaling defines a distinct subtype of acute lymphoblastic leukaemia – Markus Müschen

Inducing non-cell autonomous killing of double-hit lymphoma – David M. Weinstock

Integration of genetic and clinical information into one score, the CLL-IPI project – Jasmin Bahlo

SESSION II: ROLE OF THE LYMPHOMA MICROENVIRONMENT

Targeting the microenvironment rather than the leukemic clone with kinase inhibitors – Michael Hallek

Functional interactions between malignant and non-malignant cells in lymphoma – Hans-Guido Wendel

Dissecting the complexity of CLL microenvironment – Federico Caligaris-Cappio

Drugs targeting the TME of Hodgkin lymphoma: the clinical story of Nivolumab and other PD1/PDL1 inhibitor – Peter Borchmann

SESSION III: EPIGENETICS REGULATION IN B-CELL CANCERS

Genomic profiling and clonal evolution under treatment of CLL lymphoma – Catherine Wu

Epigenetics – Christoph Plass

Epigenomic evolution in diffuse large B-cell lymphomas – Ari Melnick

SESSION IV: DISEASE ASSESSMENT IN LYMPHOMA

PET and CT imaging in Hodgkin lymphoma – Lena Specht

Imaging and circulating tumour DNA in lymphoma – Wyndham Wilson

How to use molecular profiling to manage CLL in 2016 – Eugen Tausch

Assessment of minimal residual disease in lymphoid malignancies – Michael Kneba

SESSION V: CELLULAR AND OTHER IMMUNOTHERAPIES FOR LYMPHOID MALIGNANCIES

History and future role of immune therapy in lymphoma – Ronald Levy

Allogeneic stem cell transplantation for lymphoid malignancies – coming to an end? – David Maloney

CART for lymphoid malignancies – Michael Hudecek

Mechanisms of resistance to CART-19: acquired mutations meet alternative splicing – Andrei Thomas-Tikhonenko

PD1/PDL1 inhibitors in lymphoid malignancies – Margaret Shipp

SESSION VI: UPDATE ON NOVEL AGENTS IN NHL

Mechanisms of BCL2 inhibitors – Anthony Letai

Development of targeted agents in ALL – Charles Mullighan

Clinical application of BCL 2 inhibition – John Seymour

BTK inhibition – Jeffrey Jones

New agents in the management of NHL – Gilles Salles

SESSION VII: STRATEGIES OF INTERNATIONAL STUDY GROUPS TO INTEGRATED GENOMICS, NOVEL AGENTS AND TRADITIONAL APPROACHES INTO ONE TREATMENT CONCEPT

The US trials on NHL – Richard Little

The UK trials on NHL – Ruth Pettengell

The GCLLSG trials – Michael Hallek

The Lysa trial landscape – Franck Morschhauser

The UK trials on CLL – Peter Hillmen

SESSION VIII: TREATMENT OF RARE ENTITIES: IMPORTANT BUT RARE 

Treatment of paediatric lymphoma – Catherine Patte

Treatment of CNS lymphoma – Andres Ferreri

Treatment of Waldenström macroglobulinemia – Steven Treon

Treatment of hairy cell leukaemia – Brunangelo Falini

PANEL DISCUSSION: HOW TO ENSURE THAT BREAKTHROUGHS WILL HAPPEN NOW FOR NHL/CLL?

Biology – Louis Staudt

Recommendations for future research:

EHA research roadmap for lymphoma – Gilles Salles

ASH research roadmap for lymphoma – David M. Weinstock

Requirements for clinical breakthroughs in malignant lymphomas – Georg Lenz

Tools for the analysis of big data – Clemens Suter-Crazzolara

From the point of view of the patient:

The expectations of American patients – Brian Koffman

The expectations of European patients – Karen Van Rassel

 

 

 
Multiple Myeloma Hub Let's keep in touch! Clinical Updates on Acute Leukemias